PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1371938
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1371938
According to Stratistics MRC, the Global Intravenous Solutions Market is accounted for $13.09 billion in 2023 and is expected to reach $25.5 billion by 2030 growing at a CAGR of 10.0 % during the forecast period. Intravenous solutions, also called IV solutions, are sterile liquid treatments that are injected into a patient's veins by means of an intravenous line. These treatments are used for a variety of essential medical functions, such as rehydration, medicine delivery, and nutritional support, IV solutions are used to restore and maintain a patient's fluid and electrolyte balance, particularly when oral intake is insufficient or rapid absorption is required. They are composed of a precisely balanced blend of water, nutrients, and sometimes drugs and are a crucial part of contemporary healthcare, guaranteeing efficient treatment and patient support in a range of clinical settings, from hospitals to outpatient care, by supplying necessary fluids and medicinal chemicals straight into the bloodstream.
According to the guidelines by American Society for Parenteral and Enteral Nutrition (ASPEN), in 2020, the early parenteral nutrition should be initiated as soon as possible in the high-risk patient for whom early gastric enteral nutrition is not feasible.
As the developments involve the creation of specialized formulations with improved stability, solubility, and bioavailability. Additionally, modern ingredient technology makes it possible to create intravenous solutions that can transport a wider variety of therapeutic agents, such as complicated drugs and nutrients. As a result of these developments, it is now possible to treat a wider range of medical diseases by improving treatment efficacy and broadening the market's capacities. Therefore, the market for intravenous solutions benefits from being able to provide more sophisticated and specialized solutions, which enhance patient care and treatment outcomes and thus significantly drives the market growth.
IV solutions can be pricey, especially when made with complicated ingredients or in specialist formulations. Moreover, the price of manufacturing, packaging, and quality control can affect the overall cost of IV solutions. Hence, this pricing aspect may restrict market access, particularly in areas with limited resources or poor healthcare infrastructure.
Preventive and holistic healthcare methods are in greater demand as people grow more health-conscious. Intravenous solutions are in demand not just for medical treatment but also for wellness and vitality reasons. They are frequently used for rehydration, immunological support, and nutrient supplementation. Furthermore, customized IV therapy is becoming more and more popular as a way to reduce deficiencies, increase energy, and improve general wellbeing. Moreover, clinics and providers offer intravenous solutions that meet the wellness and performance objectives of a health-conscious generation, which thus propel the market size.
The consistency of product performance and quality, which is essential for patient safety, might be hampered by varying quality and safety standards. Moreover, the absence of unified regulations across regions can lead to disparities in manufacturing practices and product labeling, making it challenging for healthcare providers to ensure the reliability of intravenous solutions. Therefore, this lack of standardization and regulatory oversight can result in increased risks and complexities in the market, emphasizing the need for comprehensive, globally recognized guidelines to ensure the safety and efficacy of these critical medical products.
The market for intravenous solutions was significantly negatively impacted by the COVID-19 epidemic. Healthcare facilities experienced rare resource pressures and were frequently overburdened, which resulted in shortages and logistical difficulties when locating and dispensing these vital medical fluids. Additionally, investments in the healthcare industry were impeded by the economic collapse and uncertainties. Therefore, despite rising demand, the pandemic posed logistical and financial challenges for the market for intravenous solutions, adversely impacting both accessibility and supply.
The Dextran segment is estimated to hold the largest share, as these treatments are used in healthcare facilities to boost blood flow and lower the chance of clot formation, primarily during operations and other medical procedures. Additionally, these IV solutions based on dextran, function as plasma expanders, enhancing circulation and assisting in blood pressure maintenance. They are crucial in circumstances where patients can experience bleeding or need hemodynamic support. Thus, intravenous solutions based on dextran are an essential part of the larger intravenous solutions market in the healthcare sector since they are essential in sustaining patient wellbeing during medical operations.
The large volume bags segment is anticipated to have highest CAGR during the forecast period, due to a variety of uses in healthcare, such as nutrient delivery, medicine administration, and hydration, these bags are essential. Moreover, in hospitals, clinics, and other medical facilities, large-volume bags are frequently utilized to deliver effective and controlled intravenous therapy to patients. Hence, they are a backbone of the intravenous solutions market in the healthcare industry because they are flexible in accepting different types of solutions and are especially important for patients needing prolonged treatments.
Europe commanded the largest market share during the extrapolated period owing to the healthcare system's enormous patient population, the prominence of important players, the accessibility of drugs, the sophistication of the healthcare systems, and the advantageous reimbursement practices. Furthermore, the market for intravenous (IV) solutions in Europe will probably develop as a result of government support for the National Health Service and health insurance as well as industry technological advancements. Additionally, the intravenous solution market in the United Kingdom had the highest market share, while the intravenous solution market in France had the quickest rate of expansion in the continent of Europe.
Asia Pacific is expected to witness highest CAGR over the projection period, owing to rapid growth, which can be attributed to the high investment made in research by both public and private entities, as well as technological developments and an increase in the number of cooperative relationships between different stakeholders, including the healthcare industry, universities, and others. Therefore, the rising prevalence of chronic diseases brought on by unhealthy food consumption patterns and the growing choice for cost-effective care are two significant factors that are projected to propel market growth in the Asia Pacific region.
Some of the key players in the Intravenous Solutions Market include: ICU Medical, Inc., B. Braun Melsungen Ag, JW Life Science, Baxter International Inc., Fresenius Kabi USA, LLC, Vifor Pharma Management Ltd, Amanta Healthcare, Grifols, S.A, Salius Pharma Private Limited., Pfizer, Inc., Axa Parenterals Ltd, Ajinomoto Co., Inc., Otsuka Pharmaceutical Co., Ltd, Sichuan Kelun Pharmaceutical Co Ltd, Soxa Formulations & Research Pvt. Ltd and Braun Melsungen AG.
In March 2022, Otsuka Pharmaceutical received regulatory approval in Japan for the sale of SAMTASU intravenous infusion for treating cardiac edema.
In February 2022, B. Braun Medical received the US FDA approval to begin operations at its new IV saline solution manufacturing facility in Daytona Beach, Florida.
In September 2021, B. Braun Medical Inc. launched CARESAFE IV Administration Sets with an Optional AirStop component.
In July 2021, Grifols S.A. announced the establishment of an intravenous (IV) solutions production plant in Nigeria.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.